Sign Out
Pharmacology: Pharmacodynamics: Mechanism of Action: Reteplase is a recombinant plasminogen activator. It catalyzes the cleavage of endogenous plasminogen to generate plasmin. This plasminogenolysis takes place in the presence of fibrin. Plasmin in turn degrades fibrin, which is the main component of the matrix of thrombi, thereby exerting its thrombolytic action.
Clinical study on Reteplase (MIREL) demonstrated efficacy by reducing mortality in patients with ST segment elevation myocardial infarction (STEMI). Reteplase (MIREL) also decreased the frequency of re-infarction, cardiac failure, cardiac arrhythmia and need for recanalization procedure which is comparable with earlier reported Reteplase studies. There was also significant increase in LVEF and 50% lowering of ST segment in >50% of patients at 90th minute post dosing.
Pharmacokinetics: Based on the measurement of thrombolytic activity, Reteplase is cleared from plasma at a rate of 250-450 mL/min, with an effective half-life of 13-16 minutes. Reteplase is primarily cleared by the liver and kidney.
Continue with Google